Hexima Limited is pleased to announce today that the first patient has been dosed in its phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.

Hexima’s CEO Dr Nicole van der Weerden said “Advancing HXP124 into clinical testing has been a major focus for Hexima through 2017 and we are delighted to have achieved this key milestone. This study will provide important information about the safety of HXP124 and potentially the ability of HXP124 to treat fungal nail infections and is a critical step in the development of this novel topical drug.”

Click on title to read more.

Hexima Limited is pleased to announce today that it has received Human Research Ethics Committee approval to conduct a phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.

Hexima’s CEO Dr Nicole van der Weerden said “Obtaining ethics approval for our first clinical trial is a major milestone for Hexima. It is the culmination of the last three years of work to generate the required non-clinical data including preclinical safety/toxicology, efficacy testing and manufacture, formulation and stability of HXP124. The ethics committee has reviewed this data, along with our clinical study design, and granted us permission to test this molecule on human patients for the first time. This is a critical step forward in the development of HXP124 as a treatment for fungal nail infections and we are very excited to begin this next phase of development.”